(2S,3R,4S,5S)-2,5-bis[((3-hydroxyphenyl)carbonyl)amino]-3,4-dihydroxy-1,6-diphenyl-hexane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3R,4S,5S)-2,5-bis[((3-hydroxyphenyl)carbonyl)amino]-3,4-dihydroxy-1,6-diphenyl-hexane
• 英文别名: (2S,3R,4S,5S)-2,5-bis[N-[(3-hydroxyphenyl)carbonyl]amino]-3,4-dihydroxy-1,6-diphenyl hexane；N-[(1S,2S,3R,4S)-1-benzyl-2,3-dihydroxy-4-[(3-hydroxybenzoyl)amino]-5-phenyl-pentyl]-3-hydroxy-benzamide；N-[(2S,3S,4R,5S)-3,4-dihydroxy-5-[(3-hydroxybenzoyl)amino]-1,6-diphenylhexan-2-yl]-3-hydroxybenzamide
• 化学式: C₃₂H₃₂N₂O₆
• 分子量: 540.616
• InChiKey: YKSLKGFNNMLLTG-GCXHJFECSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  139
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2S,3R,4S,5S-2,5-diamino-3,4-dihydroxy-1,6-diphenyl hexane 、 间羟基苯甲酸 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N-甲基乙酰胺 、 乙酸乙酯 为溶剂， 生成 (2S,3R,4S,5S)-2,5-bis[((3-hydroxyphenyl)carbonyl)amino]-3,4-dihydroxy-1,6-diphenyl-hexane
  参考文献：
  名称：

  2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising

  摘要：

  本发明提供了2,5-二氨基-3,4-二取代-1,6-二苯基己烷（DAD）的同功异构体，包括苯甲酰胺、磺酰胺和蒽酰胺亚基，一种包括这些化合物的药物组合物，一种使用这些化合物治疗哺乳动物，尤其是人类体内的逆转录病毒，特别是HIV-1和HIV-2感染的方法，一种合成不对称DAD同功异构体包括苯甲酰胺、磺酰胺和蒽酰胺亚基的方法，以及一种使用这些化合物检测新化合物的抗逆转录病毒活性的方法。

  公开号：

  US05728718A1

文献信息

• 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising
  申请人：The United States of America as represented by the Department of Health

  公开号：US05728718A1

  公开（公告）日：1998-03-17

  The present invention provides 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide and anthranilamide subunits, a pharmaceutical composition comprising such compounds, a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans, a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide and anthranilamide subunits, and a method of using such compounds to assay new compounds for antiretroviral activity.

  本发明提供了2,5-二氨基-3,4-二取代-1,6-二苯基己烷（DAD）的同功异构体，包括苯甲酰胺、磺酰胺和蒽酰胺亚基，一种包括这些化合物的药物组合物，一种使用这些化合物治疗哺乳动物，尤其是人类体内的逆转录病毒，特别是HIV-1和HIV-2感染的方法，一种合成不对称DAD同功异构体包括苯甲酰胺、磺酰胺和蒽酰胺亚基的方法，以及一种使用这些化合物检测新化合物的抗逆转录病毒活性的方法。
• 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services

  公开号：EP0801640B1

  公开（公告）日：2003-03-26
• US6066656A
  申请人：——

  公开号：US6066656A

  公开（公告）日：2000-05-23
• [EN] 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME<br/>[FR] COMPOSES ISOSTERES DE 2,5-DIAMINO-3,4-DISUSBSTITUES-1,6-DIPHENYLHEXANE COMPRENANT DES SOUS-UNITES DE BENZAMIDE, DE SULFONAMIDE ET D'ANTHRANILAMIDE, AINSI QUE LEUR MODE D'EMPLOI
  申请人：——

  公开号：WO1996019437A1

  公开（公告）日：1996-06-27

  [EN] The present invention provides 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide and anthranilamide subunits, a pharmaceutical composition comprising such compounds, a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans, a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide and anthranilamide subunits, and a method of using such compounds to assay new compounds for antiretroviral activity.
  [FR] L'invention concerne des composés isostères de 2,5-diamino-3,4-disubstitués-1,6-diphénylhexane (DAD) comprenant des sous-unités de benzamide, de sulfonamide et d'anthranilamide, une composition pharmaceutique à base de ces composés, un mode d'utilisation de ces composés dans le traitement des infections à rétrovirus chez les mammifères, notamment les infections à VIH et plus particulièrement les infections à VIH-1 et à VIH-2 chez l'homme, un procédé de synthèse des isostères DAD dissymétriques comprenant des sous-unités de benzamide, de sulfonamide et d'anthranilamide, ainsi que le mode d'emploi de ces composés pour le dosage de nouveaux composés ayant une activité antirétrovirus.
• Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2′ replacement for the symmetry-based HIV protease inhibitors
  作者：Ramnarayan S. Randad、Lucyna Lubkowska、Abelardo M. Silva、Diego M.A. Guerin、Sergei V. Gulnik、Betty Yu、John W. Erickson

  DOI：10.1016/0968-0896(96)00140-x

  日期：1996.9

  A combination of structure-activity studies, kinetic analysis, X-ray crystallographic analysis, and modeling were employed in the design of a novel series of HIV-1 protease (HIV PR) inhibitors. The crystal structure of a complex of HIV PR with SRSS-2,5-bis[N-(tert-butyloxycarbonyl)amino]-3,4-dihydroxy-1,6-diphenylhexane (1) delineated a crucial water-mediated hydrogen bond between the tert-butyloxy group of the inhibitor and the amide hydrogen of Asp29 of the enzyme. Achiral, nonpeptidic 2-hydroxyphenylacetamide and 9-hydroxybenzamide groups were modeled as novel P2/P2' ligands to replace the crystallographic water molecules and to provide direct interactions with the NH groups of the Asp29/129 residues. Indeed, the symmetry-based inhibitors 7 and 19, possessing 3-hydroxy and 3-aminobenzamide, respectively, as a P2/P2' ligand, were potent inhibitors of HIV PR. The benzamides were superior in potency to the phenylacetamides and have four fewer rotatable bonds. An X-ray crystal structure of the HIV PR/7 complex at 2.1 Angstrom resolution revealed an asymmetric mode of binding, in which the 3-hydroxy group of the benzamide ring makes the predicted interaction with the backbone NH of Asp29 on one side of the active site only. An unexpected hydrogen bond with the Gly148 carbonyl group, resulting from rotation of the aromatic ring out of the amide plane, was observed on the other side. The inhibitory potencies of the benzamide compounds were found to be sensitive to the nature and position of substituents on the benzamide ring, and can be rationalized on the basis of the structure of the HIV PR/7 complex. These results partly confirm our initial hypothesis and suggest that optimal inhibitor designs should satisfy a requirement for providing polar interactions with Asp29 NH, and should minimize the conformational entropy loss on binding by reducing the number of freely rotatable bonds in inhibitors. Copyright (C) 1996 Elsevier Science Ltd